| Fotiadis et al.99 Fotiadis C, Xekouki P, Papalois AE, Antonakis PT, Sfiniadakis I, Flogeras D, et al. Effects of mycophenolate mofetil vs cyclosporine administration on graft survival and function after islet allotransplantation in diabetic rats. World J Gastroenterol. 2005;11(18):2733-8.
|
MMF and CsA |
12 mg/kg and 23 mg/kg (MMF) |
- |
|
|
|
5 mg/kg (CsA) |
|
| Merani et al. 1010 Merani S, Pawlick RL, Edgar RL, Toso C, Emamaullee J, Anderson CC, et al. Protein kinase C inhibitor, AEB-071, acts complementarily with cyclosporine to prevent islet rejection in rats. Transplantation. 2009;87(1):59-65.
|
AEB-071 (Protein Kinase C Inhibitory) + CsA, CTLA4-lg, MMF |
30 mg/kg (AEB-071) |
2 times a day, oral (AEB-071) |
|
|
|
2.5 mg/kg and 5 mg/kg (CsA) |
2 times a day, oral (CsA) |
|
|
|
0.25 mg (CTLA4-lg Intraperitoneal) |
0, 2, 4 and 6 PO, Intraperitoneal (CTLA4-lg) |
|
|
|
10 mg/kg (MMF) |
Once a day, oral (MMF) |
| Nishimura et al. 1111 Nishimura R, Nishioka S, Fujisawa I, Shiku H, Shimada M, Sekiguchi S, et al. Tacrolimus inhibits the revascularization of isolated pancreatic islets. PLoS One. 2013;8(4):e56799.
|
Tacrolimus |
0.5 mg/kg |
Infused subcutaneously - Daily - for 14 days |
| Makhlouf et al. 1212 Makhlouf L, Duvivier-Kali VF, Bonner-Weir S, Dieperink H, Weir GC, Sayegh MH. Importance of hyperglycemia on the primary function of allogeneic islet transplants.. Transplantation 2003;76(4):657-64.
|
Blockade of CD28:B7 and anti-CD40 L; CTLA-4 |
250 µg |
Intraperitoneal - 0, 2, 4 and 6 PO |
| Wee et al. 1313 Wee YM, Choi MY, Kang CH, Kim YH, Kim JH, Lee SK, et al. The synergistic effect of Tautomycetin on Cyclosporine A-mediated immunosuppression in a rodent islet allograft model. Mol Med. 2010;16(7-8):298-306.
|
CsA + Tautomycetin (Synergist) |
5 mg/g and 15 mg/kg (CsA) |
Once a day for 7 days |
| Watanabe et al. 1414 Watanabe M, Yamashita K, Kamachi H, Kuraya D, Koshizuka Y, Shibasaki S, et al. Efficacy of DHMEQ, a NF-kB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.. Transplantation 2013;96(5):454-62.
|
Tacrolimus and DHMEQ |
1.5 mg/kg (Tacrolimus) |
Once a day 0 to 3 PO and |
|
|
|
20 mg/kg (DHMEQ) |
2 times a day 0 to 14 PO (DHMEQ); 0 to 14 PO (Tacrolimus); |
|
|
|
|
Once a day 0 to 3 PO (DHMEQ) + 0 to 14 PO (Tacrolimus) |
| Xekouki et al. 1515 Xekouki P, Papalois A, Fotiadis C, Sfiniadakis J, Karampela E, Papadopoulou A, et al. In vivo test of two low doses of mycophenolate mofetil in an experimental model of islet allotransplantation. Transplant Proc. 2002;34(5):1446-8.
|
CsA and MMF
|
5 mg/kg (CsA) |
Oral - Daily - 12 consecutive days |
|
|
|
12 mg/kg (MMF) |
|
|
|
|
23 mg/kg (MMF) |
|
| Baker et al. 1616 Baker MS, Chen X, Rotramel AR, Nelson JJ, Lu B, Gerard C, et al. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery. 2003;134(2):126-33.
|
Monoclonal antibody antiBIP-10 |
300 µg intraperitoneal |
Daily - 14 days
|
| Vieiro et al. 1717 Vieiro M, Ceballos C, Barrionuevo P, Hyon SH, Isturiz M, Argibay P. Inhibition of allospecific response in pancreatic islet transplantation: the glycan approach.. Transplant Proc 2005;37(1):242-4.
|
Tritiated thymidine (preoperative) and CsA |
20 mg/kg (CsA) |
N/A |
| Melzi et al. 1818 Melzi R, Battaglia M, Draghici E, Bonifacio E, Piemonti L. Relevance of hyperglycemia on the timing of functional loss of allogeneic islet transplants: implication for mouse model.. Transplantation 2007;83(2):167-73.
|
Rapamycin + FK506 + anti-IL-2Ra chain mAbs and rapamycin + IL-10 |
1 mg/kg (Rapamycin) |
Intraperitoneal: Once a day - 30 PO (Rapamycin) |
|
|
|
0.05 µg/kg (IL-10) |
2 times a day - 30 days (IL-10) |
|
|
|
0.3 mg/kg (FK506) |
Once a day - 30 days (FK506) |
|
|
|
1 mg/kg (mAbs) |
0.4 PO (mAbs) |
| Fan et al. 1919 Fan K, Wang H, Wei H, Zhou Q, Kou G, Hou S, et al. Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance.. Transplantation 2007;84(6):746-54.
|
LTß R-lg, CTLA4-lg or LTR mAb anti mouse |
200 µg |
Intraperitoneal - days - 1, 1, 3, 5, 7 and 9 |
| Jung et al. 2020 Jung da Y, Kim EY, Joo SY, Park JB, Moon C, Kim SH, et al. Prolonged survival of islet allografts in mice treated with rosmarinic acid and anti- CD154 antibody. Exp. Mol Med 2008;40(1):1-10.
|
CD154 mAb (MR1) anti mouse + ROS-A |
250 µg (CD154 mAb (MR1) anti mouse) |
Intraperitoneal injection 0, 2, 4, 6 and 8 PO |
|
|
|
200 mg/kg of Ros A |
(CD154 mAb (MR1) anti mouse) |
|
|
|
|
8 consecutive days (ROS-A) |
| Påhlman et al. 2121 Påhlman C, Malm H, Qi Z, Veress B, Ferguson D, Bundick R, et al. Operational tolerance in nonvascularized transplant models induced by AR-C117977, a monocarboxylate transporter inhibitor.. Transplantation 2008;86(8):1135-8.
|
AR-C117977 or CsA |
0.2 mL - 3, 10, 30, or 100 mg/kg (AR-C117977) |
Subcutaneous - once a day 0 to 9 PO (AR-C117977) |
|
|
|
0.5 ml - 20 mg/kg (CsA) |
Once a day 0-9 PO or 0-39 PO (CsA) |
| Wang et al.2222 Wang X, Hao J, Metzger DL, Mui A, Ao Z, Verchere CB, et al. Local expression of B7-H4 by recombinant adenovirus transduction in mouse islets prolongs allograft survival.. Transplantation 2009;87(4):482-90.
|
B7-H4 |
5 plaque-forming units (pfu) of Ad-B7-H4 or Ad-LacZ |
N/A |
| Potiron et al.2323 Potiron N, Chagneau C, Boeffard F, Soulillou JP, Anegon I, Le Mauff B. Adenovirus-mediated CTLA4Ig or CD40Ig gene transfer delays pancreatic islet rejection in a rat-to-mouse xenotransplantation model after systemic but not local expression. Cell Transplant. 2005;14(5):263-75.
|
CTLA4 lg or CD40 lg |
5 x 10^9 IP of AdCTLA4 IM and/or 5 x 10^9 IM or 2 x 10^9 IV of AdCD40lg; |
IM administration - anterior tibialis muscle; IV administration - venile vein |
|
|
|
M administration: 10 µl per point (3 points) |
|
|
|
|
IV administration: 150 µl with 0.9% sodium chloride |
|
| Jahretal. 2424 Jahr H, Hussmann B, Eckhardt T, Bretzel RG. Successful single donor islet allotransplantation in the streptozotocin diabetes rat model. Cell Transplant. 2002;11(6):513-8.
|
Anti-rat antilymphocyte serum |
Intraperitoneal administration 0.5 ml |
1 day after islet transplantation |
